Danyang Chen

78 Hengzhigang Rd
Guangzhou, 510095, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Identification and validation of serum SLIT1 as a biomarker for predicting anti-PD-1/PD-L1 resistance in non-small cell lung cancer.

Identification and validation of serum SLIT1 as a biomarker for predicting anti-PD-1/PD-L1 resistance in non-small cell lung cancer.

Journal: Biological procedures online

Published: March 24, 2026

METTL14-Mediated Bim mRNA m6A Modification Augments Osimertinib Sensitivity in EGFR-Mutant NSCLC Cells.

METTL14-Mediated Bim mRNA m6A Modification Augments Osimertinib Sensitivity in EGFR-Mutant NSCLC Cells.

Journal: Molecular cancer research : MCR

Published: December 07, 2023

Methylation-modulated PFTK1 regulates gefitinib resistance via Wnt/β-catenin signaling in EGFR mutant non-small-cell lung cancer cells.

Methylation-modulated PFTK1 regulates gefitinib resistance via Wnt/β-catenin signaling in EGFR mutant non-small-cell lung cancer cells.

Journal: Communications biology

Published: November 23, 2023

Cip2a induces arginine biosynthesis and promotes tumor progression in non-small cell lung cancer.

Cip2a induces arginine biosynthesis and promotes tumor progression in non-small cell lung cancer.

Journal: Molecular carcinogenesis

Published: November 04, 2022

Smoke-induced SAV1 Gene Promoter Hypermethylation Disrupts YAP Negative Feedback and Promotes Malignant Progression of Non-small Cell Lung Cancer.

Smoke-induced SAV1 Gene Promoter Hypermethylation Disrupts YAP Negative Feedback and Promotes Malignant Progression of Non-small Cell Lung Cancer.

Journal: International journal of biological sciences

Published: March 30, 2022

P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.

P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.

Journal: Oncogene

Published: February 09, 2022

Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells.

Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells.

Journal: Cell death discovery

Published: December 21, 2021

TCRP1 activated by mutant p53 promotes NSCLC proliferation via inhibiting FOXO3a.

TCRP1 activated by mutant p53 promotes NSCLC proliferation via inhibiting FOXO3a.

Journal: Oncogenesis

Published: November 21, 2021

FOXC1 Knockdown Reverses Gefitinib Resistance in Non-small Cell Lung Cancer

FOXC1 Knockdown Reverses Gefitinib Resistance in Non-small Cell Lung Cancer

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer

Published: August 02, 2021

Histone Deacetylase Inhibitor Sensitizes ERCC1-High Non-small-Cell Lung Cancer Cells to Cisplatin via Regulating miR-149.

Histone Deacetylase Inhibitor Sensitizes ERCC1-High Non-small-Cell Lung Cancer Cells to Cisplatin via Regulating miR-149.

Journal: Molecular therapy oncolytics

Published: April 15, 2020

Showing 1-10 of 10

Last Updated: 09/26/2026